Lupin launches Loteprednol Etabonate ophthalmic suspension 0.5% in US
Loteprednol Etabonate Ophthalmic Suspension, 0.5% is indicated for the treatment of steroidresponsive inflammatory conditions of the palpebral and bulbar conjunctiva
Loteprednol Etabonate Ophthalmic Suspension, 0.5% is indicated for the treatment of steroidresponsive inflammatory conditions of the palpebral and bulbar conjunctiva
Plant-based chemistries have an outsized role to play for the HPC sector by meeting demand for good, gentle, and green products
Godavari Biorefineries receives patent from CNIPA
Finerenone significantly reduced the combined risk of cardiovascular death and total (first and recurrent) heart failure events,
India’s nutraceutical industry is expected to reach over US$ 22 billion in 2025
Capricor’s BLA for Deramiocel received Priority Review in March 2025
Celecoxib is a nonsteroidal anti-inflammatory drug
GII is a leading investment firm with assets under management exceeding US$ 3.5 billion with presence across Saudi Arabia, UAE, Europe, USA and India
LEQSELVI now available for prescription in U.S. nationwide, offering a new option for eligible patients
Subscribe To Our Newsletter & Stay Updated